Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Role of Matrix Metalloproteases in Degradation of ECM

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...

Intracellular Signaling Affects Focal Adhesions

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bioactive nanofibers enable the identification of thrombospondin 2 as a key player in enamel regeneration.

Biomaterials·2015

Same author

Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2012

Same author

Dynamic reciprocity in the wound microenvironment.

Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society·2011

Same author

Metaxin deficiency alters mitochondrial membrane permeability and leads to resistance to TNF-induced cell killing.

Protein & cell·2010

Same author

Thrombospondin-4 regulates vascular inflammation and atherogenesis.

Circulation research·2010

Same author

Expression in SPARC-null mice of collagen type I lacking the globular domain of the α1(I) N-propeptide results in abdominal hernias and loss of dermal collagen.

Matrix biology : journal of the International Society for Matrix Biology·2010

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis

Published on: December 21, 2014

Thrombospondins function as regulators of angiogenesis.

Journal of Cell Communication and Signaling

|October 3, 2009

Summary

Thrombospondins (TSPs)-1 and -2 are matricellular proteins that inhibit angiogenesis by interacting with cell receptors. Their anti-cancer potential is being explored through peptide mimetics.

Area of Science:

Biochemistry
Molecular Biology
Cell Biology

Background:

Thrombospondins (TSPs)-1 and -2 are identified as early protein inhibitors of angiogenesis.
These proteins are classified as matricellular, interacting with various molecules but lacking direct structural roles.
The functions of TSPs in angiogenesis regulation are confirmed by knockout mouse models.

Purpose of the Study:

To elucidate the mechanisms by which TSPs-1 and -2 regulate angiogenesis.
To explore the diverse functions of these multi-domain proteins beyond angiogenesis.
To investigate the therapeutic potential of TSPs as anti-tumor agents.

Main Methods:

Analysis of TSP-1 and TSP-2 interactions with endothelial cell-surface receptors (e.g., CD36, VLDLR, CD47).

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Experiment Videos

Last Updated: Jun 19, 2026

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis

Published on: December 21, 2014

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Phenotypic analysis of TSP-1, TSP-2, and double TSP-1/2-null mice.

Investigation of TSP-1's ability to activate the latent TGF-beta1 complex.

Evaluation of peptide mimetics derived from TSP type I repeats.

Main Results:

TSP-1 and TSP-2 inhibit angiogenesis through interactions with CD36, leading to endothelial cell apoptosis.
A homeostatic mechanism involving VLDLR inhibits endothelial cell proliferation.
TSP-1 antagonizes nitric oxide signaling via CD47 interaction, further inhibiting angiogenesis.
Paradoxical pro-angiogenic effects of TSP-1 are linked to domain-specific receptor interactions.

Conclusions:

TSPs-1 and -2 play critical roles in regulating angiogenesis through multiple receptor-mediated pathways.
TSP-1 exhibits distinct functions, including TGF-beta1 activation, not shared by TSP-2.
The anti-angiogenic properties of TSPs support their investigation as anti-cancer therapeutics, with peptide mimetics in clinical trials.